. 2015 Aug 27;2015(8):CD007603. doi: 10.1002/14651858.CD007603.pub2

9. MMF: adverse effects.

Category	Study	Details of adverse event	MMF Number of events/Number followed up	Control* Number of events/Number followed up
Epithelial keratitis	Birnbaum 2009		Not reported
Epithelial keratitis	Reinhard 2001		Not reported
High intraocular pressure	Birnbaum 2009		Not reported
High intraocular pressure	Reinhard 2001	Glaucoma	1/29	2/27
Major calcineurin‐inhibitor toxicity	Birnbaum 2009	Hyperglycaemia	7/57	4/41
Major calcineurin‐inhibitor toxicity	Reinhard 2001	Hepatotoxicity	2/29	3/27
Minor calcineurin‐inhibitor toxicity	Birnbaum 2009
Minor calcineurin‐inhibitor toxicity	Reinhard 2001	Gingival problems	0	3/41
Dose reductions due to adverse events	Birnbaum 2009	Due to raised liver enzymes	2/57	0
Dose reductions due to adverse events	Reinhard 2001		Not reported
Withdrawals and dropouts due to adverse events	Birnbaum 2009	Gastrointestinal disturbances (1) Asthma, pruritus, and fatigue (1)	2/57	0
Withdrawals and dropouts due to adverse events	Reinhard 2001		2/29	2/27

Birnbaum 2009 control group received systemic and topical corticosteroids same as MMF group.

Reinhard 2001 control group received systemic cyclosporine A.

MMF: mycophenolate mofetil

Other adverse effects reported in MMF group in Birnbaum 2009: Hyperlipidaemia (11), Infections (8), Tachycardia (4), Weight loss (4), Fatigue (4), Weight gain (3), Insomnia (3), Headache (3), Malignancies (2), Myalgia (1), Renal colic (1), Myocardial infarction (1), Erythema (1), Deterioration of atopic eczema (1), Muscular cramps (1), Paresthesia (1), Ostealgia (1), Agranulocytosis (1), Anaemia (1).